Literature DB >> 29701996

An Alternative Approach for the Analysis of Time-to-Event and Survival Outcomes in Pulmonary Medicine.

Michael O Harhay1, Raphaël Porcher2,3,4, Edward Cantu1, Michael J Crowther5, Jason D Christie1, Gabriel Thabut6,7, Gavin C Donaldson8.   

Abstract

Mesh：

Year:  2018        PMID： 29701996      PMCID： PMC6118012          DOI： 10.1164/rccm.201801-0189LE

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  10 in total

1.  Interpreting hazard ratios.

Authors:  Philip Sedgwick; Katherine Joekes
Journal:  BMJ       Date:  2015-08-28

2.  The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt.

Authors:  Patrick Royston; Mahesh K B Parmar
Journal:  Stat Med       Date:  2011-05-25       Impact factor: 2.373

3.  Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis.

Authors:  Hajime Uno; Brian Claggett; Lu Tian; Eisuke Inoue; Paul Gallo; Toshio Miyata; Deborah Schrag; Masahiro Takeuchi; Yoshiaki Uyama; Lihui Zhao; Hicham Skali; Scott Solomon; Susanna Jacobus; Michael Hughes; Milton Packer; Lee-Jen Wei
Journal:  J Clin Oncol       Date:  2014-06-30       Impact factor: 44.544

4.  Restricted Mean Survival Time as a Measure to Interpret Clinical Trial Results.

Authors:  Dae Hyun Kim; Hajime Uno; Lee-Jen Wei
Journal:  JAMA Cardiol       Date:  2017-11-01       Impact factor: 14.676

5.  Efficiency of two sample tests via the restricted mean survival time for analyzing event time observations.

Authors:  Lu Tian; Haoda Fu; Stephen J Ruberg; Hajime Uno; Lee-Jen Wei
Journal:  Biometrics       Date:  2017-09-12       Impact factor: 2.571

6.  On the restricted mean survival time curve in survival analysis.

Authors:  Lihui Zhao; Brian Claggett; Lu Tian; Hajime Uno; Marc A Pfeffer; Scott D Solomon; Lorenzo Trippa; L J Wei
Journal:  Biometrics       Date:  2015-08-24       Impact factor: 2.571

7.  Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies.

Authors:  Hajime Uno; Janet Wittes; Haoda Fu; Scott D Solomon; Brian Claggett; Lu Tian; Tianxi Cai; Marc A Pfeffer; Scott R Evans; Lee-Jen Wei
Journal:  Ann Intern Med       Date:  2015-07-21       Impact factor: 25.391

8.  Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio.

Authors:  Kyongsun Pak; Hajime Uno; Dae Hyun Kim; Lu Tian; Robert C Kane; Masahiro Takeuchi; Haoda Fu; Brian Claggett; Lee-Jen Wei
Journal:  JAMA Oncol       Date:  2017-12-01       Impact factor: 31.777

9.  Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome.

Authors:  Patrick Royston; Mahesh K B Parmar
Journal:  BMC Med Res Methodol       Date:  2013-12-07       Impact factor: 4.615

10.  Life expectancy difference and life expectancy ratio: two measures of treatment effects in randomised trials with non-proportional hazards.

Authors:  Hakim-Moulay Dehbi; Patrick Royston; Allan Hackshaw
Journal:  BMJ       Date:  2017-05-25
  10 in total
  4 in total

1.  Restricted Mean Survival Time for Survival Analysis: A Quick Guide for Clinical Researchers.

Authors:  Kyunghwa Han; Inkyung Jung
Journal:  Korean J Radiol       Date:  2022-05       Impact factor: 7.109

2.  Donor Lung Sequence Number and Survival after Lung Transplantation in the United States.

Authors:  Michael O Harhay; Raphaël Porcher; Gabriel Thabut; Michael J Crowther; Thomas DiSanto; Samantha Rubin; Zachary Penfil; Zhou Bing; Jason D Christie; Joshua M Diamond; Edward Cantu
Journal:  Ann Am Thorac Soc       Date:  2019-03

3.  Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: Combined data from two prospective observational studies.

Authors:  Anthony J Garcia-Prats; H Simon Schaaf; Heather R Draper; Maria Garcia-Cremades; Jana Winckler; Lubbe Wiesner; Anneke C Hesseling; Rada M Savic
Journal:  PLoS Med       Date:  2019-04-30       Impact factor: 11.069

4.  ALS in Finland: Major Genetic Variants and Clinical Characteristics of Patients With and Without the C9orf72 Hexanucleotide Repeat Expansion.

Authors:  Hannu Laaksovirta; Jyrki Launes; Lilja Jansson; Bryan J Traynor; Karri Kaivola; Pentti J Tienari
Journal:  Neurol Genet       Date:  2022-03-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.